DocTIS researcher Yolanda Guillén to present at ISCO 2026 conference in Barcelona
Dr. Yolanda Guillén, Bioinformatics Scientist at project partner IMIDomics and member of the DocTIS team, will present her research at the Innovations in Single Cell Omics (ISCO 2026) conference, taking place in Barcelona on 28–29 May 2026.
Yolanda will present a poster titled “Longitudinal single-cell profiling of therapeutic response in six immune-mediated inflammatory diseases”, showcasing results generated within the DocTIS project. The study analyses longitudinal single-cell transcriptomic data from patients with IMIDs to characterise heterogeneous responses to targeted therapies. By identifying immune cell programmes associated with treatment response, the work contributes directly to DocTIS objectives of understanding variability in therapeutic outcomes and supporting the identification of more effective, personalised treatment strategies.
The poster will be presented during the session on 28 May, starting at 17:50, as part of a programme featuring selected contributions from researchers working at the forefront of single-cell and spatial omics.
ISCO has established itself as a specialised international meeting focused on single-cell omics, bringing together researchers from leading academic and biomedical institutions. Co-organised by major research centres in Berlin and Barcelona, the conference places a strong emphasis on scientific exchange among early-career researchers while maintaining a high-quality programme with keynote speakers and selected abstract presentations. The conference will be held at the PRBB Auditorium (Centre for Genomic Regulation, CRG) and features contributions from internationally recognised institutions such as CeMM, EPFL, University of Oxford, Stanford University and EMBL-EBI. It has reached full capacity for its 2026 edition, reflecting strong interest from the international research community.
The agenda highlights recent advances in areas such as cellular perturbations, lineage tracing, spatial omics and single-cell epigenomics. Notable sessions include keynote lectures on single-cell biology and cell engineering, as well as dedicated sessions on the translation of omics approaches into clinical research.
Registrations for ISCO 2026 are now closed, as the maximum capacity of the venue has been reached. More information about the conference: https://www.isco-conference.eu/
DocTIS (Decision on Optimal Combinatorial Therapies in IMIDs using Systems Approaches) is a European research project focused on improving treatment strategies for six immune-mediated inflammatory diseases (IMIDs): rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn’s disease and systemic lupus erythematosus. The project aims to identify effective combinatorial therapies through the integration of high-dimensional molecular data and systems biology approaches.
Partners include the Vall d’Hebron Research Institute, VHIR (Sara Marsal), Cardiff University (Ernest Choy), the University of Verona (Giampiero Girolomoni), Charité – Universitätsmedizin Berlin (Britta Siegmund), the Institut d’Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS (Pere Santamaria), the National Center for Genomic Analysis, CNAG (Holger Heyn), IMIDomics Inc. (Manuel Lopez-Figueroa), HudsonAlpha Institute for Biotechnology (Richard M. Myers) and Zabala Innovation.
